Florholmen J, Burhol P G, Jenssen T G, Jorde R
Scand J Gastroenterol. 1985 Sep;20(7):829-34. doi: 10.3109/00365528509088830.
In six healthy volunteers there were no significant changes during a 300-min control period, whereas gastric inhibitory polypeptide in pharmacological doses first caused a transient and non-significant decrease and then a significant increase in the serum cationic trypsin-like immunoreactivity (CTLI). In another two groups of six healthy subjects, pharmacological doses of cholecystokinin elicited a non-significant increase, whereas somatostatin in pharmacological doses first caused a significant decrease and then a rebound effect with significantly higher levels of serum CTLI.
在6名健康志愿者中，300分钟的对照期内未出现显著变化，而药理剂量的胃抑制性多肽首先导致血清阳离子胰蛋白酶样免疫反应性（CTLI）短暂且不显著地降低，随后显著升高。在另外两组各6名健康受试者中，药理剂量的胆囊收缩素引起不显著的升高，而药理剂量的生长抑素首先导致显著降低，然后出现反跳效应，血清CTLI水平显著升高。
